CD8A and neoplasm: Cancer immunotherapy has emerged as an effective clinical modality for the treatment of malignant tumors that aims to enhance the patient’s antitumor immunity by activating tumor-specific CD8+ T cells and improving the suppressed tumor immune microenvironment [37].